See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Brandon Capital is Australasia's leading life science venture capital firm that transforms promising medical research breakthroughs into medical therapies that improve patients' lives. The firm supports life science companies from proof-of-concept through to commercialisation, providing early-stage seed investment through to expansion capital. Brandon Capital has supported more than 50 start-up companies to date, the majority of which were founded by the firm in collaboration with inventors and their research institutes. Through Brandon BioCatalyst, a unique collaboration of Australian superannuation funds, CSL, Australian and New Zealand governments, state governments and more than 50 leading medical research institutes and research hospitals, the firm sources and creates deals. Brandon Capital focuses on emerging biomedical technologies with strong commercial potential, translating exciting discoveries into high-growth firms that positively impact human health.
Notable quotes
“We're excited to welcome the National Reconstruction Fund Corporation to our sixth fund, joining HESTA, Hostplus, CSL, QIC and the WA Government. Closing at $439 million, BB6 is our largest fund to date, and we remain committed to advancing breakthrough biomedical innovations.”
“Medical science has long development timelines, and it is important for the NRFC to make early and considered investments in the sector to attract the talent and capital that we will need to build our local commercialisation capabilities. If we want medical science jobs and industries to exist in Australia in ten years, we need to invest in them today.”
“Chris and I, along with the entire Brandon team, are very aware of the privilege and responsibility we have to continue delivering returns for all our stakeholders; outcomes for patients, STEM jobs for our children and grandchildren, economic diversification, and returns for investors.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| OncoRes Medical | Series A | $19m | 2026-02 |
| Vaxxas | Series D | $32m | 2025-08 |
| NRG Therapeutics | Series B | — | 2025-09 |
| PolyActiva | Series C | — | 2025-05 |
| Myricx Bio | Series A | $120m | 2024-07 |
| Pheon Therapeutics | Series A | $68m | 2022-07 |
| CatalYm | unknown | — | — |
| AstronauTx | unknown | — | — |
| Advancell | unknown | — | — |
| EBR Systems | unknown | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Sofinnova Partners | 2 |
| Forbion | 1 |
| Atlas Venture | 1 |
Fit check
Is Brandon Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit